<DOC>
	<DOCNO>NCT00643045</DOCNO>
	<brief_summary>To evaluate safety efficacy two dose range safinamide ( High Dose : 150 200 mg/day Low Dose : 50 100 mg/day ) orally , compare Placebo , add-on therapy patient early idiopathic Parkinson 's disease currently receive stable dose single dopamine agonist . It hypothesize , 24-week period , add-on treatment safinamide result great improvement motor symptom patient , compare treatment dopamine agonist alone .</brief_summary>
	<brief_title>Safinamide Add-On Therapy Patients With Early Idiopathic Parkinson 's Disease Treated With Stable Dose Single Dopamine Agonist</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agonists</mesh_term>
	<criteria>Patients diagnosis idiopathic Parkinson 's disease le 5 year duration , Hoehn Yahr Stage I III , receive treatment single dopamine agonist stable dose least 4 week prior Visit 1 ( Screening ) . Patients medical condition and/or take concomitant medication would put risk , interfere study evaluation , make unable complete requirement study ; patient diagnosis recent history substance abuse , history psychosis , depress , evidence dementia cognitive dysfunction , experience end dose wearingoff ; female patient childbearing potential ; patient previously receive safinamide .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Parkinson Disease</keyword>
</DOC>